Working... Menu

Vibe First In Human Study for the Assessment of Safety and Initial Performance of the Vibe Delivery System in Subjects With Idiopathic Overactive Bladder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03874780
Recruitment Status : Recruiting
First Posted : March 14, 2019
Last Update Posted : March 20, 2019
Information provided by (Responsible Party):
Vensica Medical Ltd.

Brief Summary:
This First In Human study is aimed to evaluate the safety and initial efficacy of the Vibe delivery system in delivering Botox (TM) to the bladder wall in patients diagnosed with overactive bladder.

Condition or disease Intervention/treatment Phase
Overactive Bladder Device: Vibe Delivery system Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First in Human (FIH) Study for the Evaluation of the Safety and Early Performance of the Vibe Delivery System for the Delivery of Botox™ in Subjects With Idiopathic Overactive Bladder (OAB)
Actual Study Start Date : January 29, 2019
Estimated Primary Completion Date : March 31, 2019
Estimated Study Completion Date : March 31, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment
Subjects treated with Botox (TM) with the Vibe investigational delivery system
Device: Vibe Delivery system
delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system

Primary Outcome Measures :
  1. Serious Adverse Events Reporting [ Time Frame: 7 days ]
    Incidence of device related SAEs

Secondary Outcome Measures :
  1. Serious Adverse Events Reporting [ Time Frame: 12 weeks ]
    Incidence of device related SAEs within

  2. Incontinence [ Time Frame: 12 weeks ]
    Change from Baseline in the mean number of Episodes of Urinary Incontinence/24h, as assessed by urinary diary

  3. Micturition [ Time Frame: 12 weeks ]
    Change from Baseline in frequency of Micturition Episodes/24h, as assessed by urinary diary

  4. Nocturia [ Time Frame: 12 weeks ]
    Change from Baseline in Daily Average Number of Nocturia Episodes, as assessed by urinary diary

  5. Urgency [ Time Frame: 12 weeks ]
    Change from baseline in Urinary urgency, as assessed by urinary diary

Other Outcome Measures:
  1. Treatment Response [ Time Frame: 12 weeks ]
    Percentage of subjects who have a Positive Treatment Response on the Treatment Benefit Scale (TBS)

  2. Change in Quality of Life Total Score [ Time Frame: 12 weeks ]
    Change from baseline in Overactive Bladder Quality of life (OAB-q) total score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Female subjects between the ages of 18 to 80 years old diagnosed with idiopathic OAB.
  2. Subject has signed Informed Consent Form and is willing and able to comply with all requirements of the protocol.
  3. Subjects with symptoms of incontinence associated with OAB for ≥ 3 months prior to screening.
  4. Subjects who are non-responsive, non-compliant or intolerable to pharmacologic oral therapy (e.g., anticholinergic agents).
  5. Subject is willing and able to initiate self-catheterization post-treatment, if required.
  6. Subjects with PVR ≤200 ml.
  7. Subjects who are mentally competent, with the ability to understand and comply with the requirements of the study.
  8. A negative urine pregnancy test during screening in women with childbearing potential. A female subject will also agree to use an adequate birth control method for the duration of her participation in the study and for a period of 6 months after participation completion.

Exclusion Criteria:

  1. Subjects currently using Clean intermittent catheterization (CIC) or indwelling catheter to manage their urinary incontinence.
  2. Pregnant or breastfeeding women, or women of childbearing potential who are planning to become pregnant during the study period or not practicing reliable contraception methods.
  3. Subjects with clinically significant Bladder Outlet Obstruction (BOO) according to medical history.
  4. Subjects with active urinary tract infection, as diagnosed on screening urinalysis.
  5. Subjects with known polyuria or polydipsia.
  6. Subjects with a known positive diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, or Amyotrophic Lateral Sclerosis.
  7. Subjects with OAB due to any known neurological reason.
  8. Subjects currently undergoing biofeedback, pelvic muscle rehabilitation, pelvic floor physical therapy, or electrical-stimulation who are unwilling to discontinue such treatments for the duration of study participation.
  9. Subject with a 24-hour total urine volume voided greater than 3,000 ml, as measured at screening visit.
  10. Predominance of stress incontinence in the opinion of the investigator, determined by medical history.
  11. Subjects with vesico-ureteral reflux, genitourinary fistulae.
  12. Subjects with pelvic organ prolapse stage III or IV, (i.e. the most distal part of the prolapse protruding more than 1 cm beyond the hymen at straining).
  13. Subjects with prior Botox™ therapy of any serotype within 12 weeks for any indication, including urologic condition.
  14. Subjects with a history of pelvic radiation therapy.
  15. Subject who is morbidly obese (BMI > 40 Kg/m2).
  16. Subjects with a history of treatment for two or more UTIs within 6 months prior to screening or use of prophylactic antibiotics to prevent chronic UTIs.
  17. Subjects on immunomodulatory therapy (suppressive or stimulatory).
  18. History or evidence of any pelvic or lower tract genitourinary abnormalities, malignancy, bladder surgery (excluding stress incontinence or pelvic organ prolapse surgeries), or disease, other than OAB.
  19. Subjects with operative sling erosion.
  20. History of interstitial cystitis/painful bladder syndrome, in the opinion of the investigator.
  21. Subjects with current major psychiatric disorder or other psychiatric or medical issues that would interfere with study participation (e.g. dementia, psychosis, upcoming major surgery, etc).
  22. Subject has severe cardiac, pulmonary, renal, or hepatic disease that in the judgment of the study physician would preclude participation in this study.
  23. Any other condition or medical history, that to the discretion of the investigator and/or Sponsor, excludes the subject from participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03874780

Layout table for location contacts
Contact: ‪Maya Shick‬ 972523355442
Contact: Avner Geva 972544959544

Layout table for location information
Jablonec Nad Nisou Medical Center Recruiting
Jablonec Nad Nisou, Czechia
Contact: Jaroslav Vseticka, MD    420483345700   
Principal Investigator: Jaroslav Vseticka, MD         
Braga Medical Center Not yet recruiting
Braga, Portugal
Contact: Agostinho Cordeiro, MD    351936716025   
Principal Investigator: Vitor Hugo, MD         
Sponsors and Collaborators
Vensica Medical Ltd.
Layout table for investigator information
Study Director: ‪Maya Shick‬ Consultant

Layout table for additonal information
Responsible Party: Vensica Medical Ltd. Identifier: NCT03874780     History of Changes
Other Study ID Numbers: CL-100
First Posted: March 14, 2019    Key Record Dates
Last Update Posted: March 20, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms